STEREOTYPIC NEUTRALIZING VH CLONOTYPES AGAINST SARS-COV-2 RBD IN COVID-19 PATIENTS AND THE HEALTHY POPULATION
Described are stereotypic-naïve SARS-CoV-2 neutralizing antibodies that inhibit that SARS-CoV-2 virus replication. The antibodies comprise variable heavy chain (VH) clonotypes, encoded by either immunoglobulin heavy variable (IGHV)3-53 or IGHV3-66 and immunoglobulin heavy joining (IGHJ)6, and were identified in IgM, IgG3, IgG1, IgA1, IgG2, and IgA2 subtypes, with minimal somatic mutations, and could be paired with diverse light chains, resulting in binding to the SARS-CoV-2 receptor-binding domain (RBD). One of these clonotypes potently inhibited viral replication. Interestingly, these VH clonotypes pre-existed in six of 10 healthy individuals, predominantly as IgM isotypes, which could explain the expeditious and stereotypic development of these clonotypes among SARS-CoV-2 patients.
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Europäisches Patentamt - (2021) vom: 30. Dez. Zur Gesamtaufnahme - year:2021 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
CHUNG JUNHO [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2021-12-30, Last update posted on www.tib.eu: 2024-02-28, Last updated: 2024-03-08 |
|---|
| Patentnummer: |
WO2021260532 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA012688967 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA012688967 | ||
| 003 | DE-627 | ||
| 005 | 20240308101810.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230215s2021 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA012688967 | ||
| 035 | |a (EPA)WO2021260532 | ||
| 035 | |a (EPA)79023129 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a CHUNG JUNHO |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a STEREOTYPIC NEUTRALIZING VH CLONOTYPES AGAINST SARS-COV-2 RBD IN COVID-19 PATIENTS AND THE HEALTHY POPULATION |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2021-12-30, Last update posted on www.tib.eu: 2024-02-28, Last updated: 2024-03-08 | ||
| 520 | |a Described are stereotypic-naïve SARS-CoV-2 neutralizing antibodies that inhibit that SARS-CoV-2 virus replication. The antibodies comprise variable heavy chain (VH) clonotypes, encoded by either immunoglobulin heavy variable (IGHV)3-53 or IGHV3-66 and immunoglobulin heavy joining (IGHJ)6, and were identified in IgM, IgG3, IgG1, IgA1, IgG2, and IgA2 subtypes, with minimal somatic mutations, and could be paired with diverse light chains, resulting in binding to the SARS-CoV-2 receptor-binding domain (RBD). One of these clonotypes potently inhibited viral replication. Interestingly, these VH clonotypes pre-existed in six of 10 healthy individuals, predominantly as IgM isotypes, which could explain the expeditious and stereotypic development of these clonotypes among SARS-CoV-2 patients | ||
| 650 | 4 | |a tec | |
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a G01N: Investigating or analysing materials by determining their chemical or physical properties (measuring or testing processes other than immunoassay, involving enzymes or microorganisms c12m, c12q) | |
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a C07K: Peptides (peptides containing β-lactam rings c07d;cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, c07d;ergot alkaloids of the cyclic peptide type c07d0519020000; single cell proteins, enzymes c12n;genetic engineering processes for obtaining peptides c12n0015000000) | |
| 650 | 4 | |a che | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a KIM SANG IL |4 aut | |
| 700 | 0 | |a KIM SUJEONG |4 aut | |
| 700 | 0 | |a NOH JINSUNG |4 aut | |
| 700 | 0 | |a CHOI YOUNGGEUN |4 aut | |
| 700 | 0 | |a YOO DUCK KYUN |4 aut | |
| 700 | 0 | |a LEE YONGHEE |4 aut | |
| 700 | 0 | |a LEE HYUNHO |4 aut | |
| 700 | 0 | |a PARK WAN BEOM |4 aut | |
| 700 | 0 | |a OH MYOUNG-DON |4 aut | |
| 700 | 0 | |a KWON SUNGHOON |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2021) vom: 30. Dez. |
| 773 | 1 | 8 | |g year:2021 |g day:30 |g month:12 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/79023129/publication/WO2021260532A1?q=WO2021260532 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 951 | |a AR | ||
| 952 | |j 2021 |b 30 |c 12 | ||